Business Wire · IBRX · November 9, 2026

ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial

Get the app for more

Explore stock news, insights and company research.